-+ 0.00%
-+ 0.00%
-+ 0.00%

Apotex Q2 adjusted EBITDA excluding VLLP rises 19% to CAD 279.8 million

PUBT·11/12/2026 11:35:20
Listen to the news
Apotex Q2 adjusted EBITDA excluding VLLP rises 19% to CAD 279.8 million
  • Apotex’s second-quarter FY27 net income rose 22% year over year to CAD 100.8 million.
  • Quarterly revenue edged up to CAD 852.9 million.
  • First-half net income dropped 86% to CAD 62.4 million, while revenue fell 14% to CAD 1.7 billion year over year.
  • Approximately 60 products launched in the first half, with 70% first to market in Canada and the United States.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apotex Health Corp. published the original content used to generate this news brief via CNW (Ref. ID: 202611120559CANADANWCANADAPR_C0371) on November 12, 2026, and is solely responsible for the information contained therein.